Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion
Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME followi...
Saved in:
Published in | Scientific reports Vol. 11; no. 1; pp. 8303 - 7 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
15.04.2021
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group. |
---|---|
AbstractList | Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group. Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group. Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group. Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group.Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of dexamethasone intravitreal implants (DII, Ozurdex) in a real-life cohort of 99 patients with ME due to RVO. All patients who received DII for ME following RVO between 2011 and 2016 at the University Eye Hospital Freiburg, Germany and who had fully accessible electronic medical records were eligible for this study. Most of the patients included in this study were not treatment-naïve: 61 eyes had received prior anti-VEGF drugs, 6 eyes had received intravitreal corticosteroids (triamcinolone) and 15 had been treated with both; 17 eyes were treatment-naïve. Mean follow-up was 312 ± 310 days. Mean visual acuity (VA) was maintained throughout the observation period (mean VA at baseline: 66.7 ± 23.5 letters; at last observation 64.9 ± 28.3). Central retinal thickness (CRT) decreased from 526 ± 179 µm at baseline to 431 ± 199 µm. Mean intraocular pressure (IOP) increased from 14.4 ± 3.1 mmHg at baseline to 17.1 ± 6.3 mmHg. Cataract surgery was performed in 22% of phakic eyes. DII was used as second-line treatment in the majority of cases in this cohort. The fact that mean VA remained unchanged while mean CRT decreased illustrates that morphologic improvement does not always translate into functional gain. Mean IOP was maintained within normal limits and cataract formation was as expected in this age group. |
ArticleNumber | 8303 |
Author | Stahl, Andreas Böhringer, Daniel Agostini, Hansjürgen Wecker, Thomas Grundel, Bastian Trick, Simon Lange, Clemens Grundel, Milena Bründer, Marie-Christine |
Author_xml | – sequence: 1 givenname: Thomas surname: Wecker fullname: Wecker, Thomas email: tw@augenarzt-wecker.de organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Ophthalmic Practice Dr. Wecker – sequence: 2 givenname: Bastian surname: Grundel fullname: Grundel, Bastian organization: Department of Ophthalmology, University Medical Center – sequence: 3 givenname: Milena surname: Grundel fullname: Grundel, Milena organization: Department of Ophthalmology, University Medical Center – sequence: 4 givenname: Marie-Christine surname: Bründer fullname: Bründer, Marie-Christine organization: Department of Ophthalmology, University Medical Center – sequence: 5 givenname: Simon surname: Trick fullname: Trick, Simon organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Department of Ophthalmology, University Medical Center – sequence: 6 givenname: Clemens surname: Lange fullname: Lange, Clemens organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg – sequence: 7 givenname: Daniel surname: Böhringer fullname: Böhringer, Daniel organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg – sequence: 8 givenname: Hansjürgen surname: Agostini fullname: Agostini, Hansjürgen organization: Eye Center, Medical Center, Faculty of Medicine, University of Freiburg – sequence: 9 givenname: Andreas surname: Stahl fullname: Stahl, Andreas organization: Department of Ophthalmology, University Medical Center |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33859243$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktv1DAUhS1UREvpH2CBIrFhE_AjiZ0NEqp4VKqEhGBtOfbN1CMnHmxngH_P7aSUtotm49j-zvHx9X1OjuY4AyEvGX3LqFDvcsPaXtWUs1rJppN194SccNq0NRecH935PyZnOW8pfi3vG9Y_I8dCqLbnjTgh8A1MqIMfoZrA-WWqCqSpGmMI8Ve97CpnisFpqvxcktn7klBQOfhtJihXJmOqyk-7YOaCSJWg-BmBPeAkWhuW7OP8gjwdTchwdjOekh-fPn4__1Jffv18cf7hsrZtQ0stLbNODrSXo2IDc0Z0Q9u5VqqBWSExvGXSUeikbCXngtpBAO34OAjnBurEKblYfV00W71LfjLpj47G68NCTBttUvE2gDYdU0rS0SkmG676wQAfBNrJkVEKHL3er167ZcDSWLi-f7hnen9n9ld6E_da0ZZy2aPBmxuDFH8ukIuefLYQsFQQl6x5y5qONlQ2iL5-gG7jkrCOB0rQnqMlUq_uJrqN8u81EeArYFPMOcF4izCqr7tGr12jsWv0oWt0hyL1QGR9MQVfDW_lw-NSsUoznjNvIP2P_YjqL3fY1rE |
CitedBy_id | crossref_primary_10_1016_j_bj_2023_100607 crossref_primary_10_1136_bmjophth_2024_001722 crossref_primary_10_3389_fmed_2024_1454591 crossref_primary_10_3389_fphar_2022_1029584 crossref_primary_10_7759_cureus_80391 crossref_primary_10_12677_ACM_2023_1371619 crossref_primary_10_1007_s00417_021_05369_9 |
Cites_doi | 10.1159/000494224 10.18637/jss.v040.i01 10.1007/s00417-016-3431-x 10.1001/archopht.124.5.726 10.1155/2020/6830148 10.1155/2017/5831682 10.1159/000442258 10.18637/jss.v021.i12 10.1080/15569527.2019.1614020 10.1016/j.ophtha.2011.05.014 10.1016/j.jcjo.2018.12.005 10.1016/j.ophtha.2010.03.032 10.1007/s00417-018-4016-7 10.1007/s00417-008-0926-0 10.1016/j.exer.2019.01.006 10.1007/s00347-012-2737-2 10.1016/j.ophtha.2009.07.017 10.1159/000473864 10.1016/j.ophtha.2010.01.060 10.1167/iovs.05-0981 10.4103/ijo.IJO_382_19 10.1007/s00417-017-3852-1 10.1038/s41598-019-38934-8 10.4103/ijo.IJO_1905_18 |
ContentType | Journal Article |
Copyright | The Author(s) 2021 The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2021 – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 5PM DOA |
DOI | 10.1038/s41598-021-87467-6 |
DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central (New) Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2045-2322 |
EndPage | 7 |
ExternalDocumentID | oai_doaj_org_article_a618870fd8174289bae2b33e07f100e2 PMC8050279 33859243 10_1038_s41598_021_87467_6 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Albert-Ludwigs-Universität Freiburg im Breisgau (1016) – fundername: ; |
GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI Q9U 7X8 AARCD 5PM PUEGO |
ID | FETCH-LOGICAL-c540t-7c1cd7b097f81b1da36b56d578b1c37941c17d0e677572230cb3e062fb3ddb0d3 |
IEDL.DBID | M48 |
ISSN | 2045-2322 |
IngestDate | Wed Aug 27 01:13:40 EDT 2025 Thu Aug 21 13:57:21 EDT 2025 Tue Aug 05 09:24:47 EDT 2025 Fri Jul 25 10:03:43 EDT 2025 Thu Apr 03 07:08:28 EDT 2025 Thu Apr 24 23:03:59 EDT 2025 Tue Jul 01 01:07:57 EDT 2025 Fri Feb 21 02:39:09 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c540t-7c1cd7b097f81b1da36b56d578b1c37941c17d0e677572230cb3e062fb3ddb0d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-021-87467-6 |
PMID | 33859243 |
PQID | 2513092502 |
PQPubID | 2041939 |
PageCount | 7 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a618870fd8174289bae2b33e07f100e2 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8050279 proquest_miscellaneous_2514604074 proquest_journals_2513092502 pubmed_primary_33859243 crossref_primary_10_1038_s41598_021_87467_6 crossref_citationtrail_10_1038_s41598_021_87467_6 springer_journals_10_1038_s41598_021_87467_6 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-04-15 |
PublicationDateYYYYMMDD | 2021-04-15 |
PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-15 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Scientific reports |
PublicationTitleAbbrev | Sci Rep |
PublicationTitleAlternate | Sci Rep |
PublicationYear | 2021 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Lange, Feltgen, Junker, Schulze-Bonsel, Bach (CR8) 2009; 247 Schulze-Bonsel, Feltgen, Burau, Hansen, Bach (CR9) 2006; 47 Nicula, Nicula, Rednik, Bulboaca, Crișan (CR23) 2020; 2020 McIntosh (CR4) 2010; 117 Pielen (CR13) 2017; 2017 Wickham (CR11) 2011; 40 Schmitz (CR20) 2014; 111 Haller (CR19) 2011; 118 Winterhalter (CR16) 2018; 256 Haller (CR18) 2010; 117 Hanhart, Rozenman (CR17) 2017; 238 Li (CR2) 2019; 241 Cugati, Wang, Rochtchina, Mitchell (CR3) 2006; 124 Wickham (CR12) 2007; 21 Teja, Sawatzky, Wiens, Maberley, Ma (CR22) 2019; 54 Hu (CR5) 2019; 67 Georgalas (CR21) 2019; 38 Rogers (CR1) 2010; 117 Walz (CR6) 2019; 181 Eter (CR14) 2017; 255 Chiquet (CR15) 2016; 55 (CR10) 2014 Wecker (CR7) 2019; 9 Blanc (CR24) 2018; 256 S Rogers (87467_CR1) 2010; 117 N Eter (87467_CR14) 2017; 255 H Wickham (87467_CR11) 2011; 40 S Winterhalter (87467_CR16) 2018; 256 J Blanc (87467_CR24) 2018; 256 JA Haller (87467_CR19) 2011; 118 S Cugati (87467_CR3) 2006; 124 RL McIntosh (87467_CR4) 2010; 117 JM Walz (87467_CR6) 2019; 181 C Nicula (87467_CR23) 2020; 2020 J Hanhart (87467_CR17) 2017; 238 K Schulze-Bonsel (87467_CR9) 2006; 47 L Georgalas (87467_CR21) 2019; 38 C Chiquet (87467_CR15) 2016; 55 JA Haller (87467_CR18) 2010; 117 K Schmitz (87467_CR20) 2014; 111 JQ Li (87467_CR2) 2019; 241 S Teja (87467_CR22) 2019; 54 C Lange (87467_CR8) 2009; 247 T Wecker (87467_CR7) 2019; 9 Q Hu (87467_CR5) 2019; 67 R Core Team (87467_CR10) 2014 H Wickham (87467_CR12) 2007; 21 A Pielen (87467_CR13) 2017; 2017 |
References_xml | – volume: 241 start-page: 183 year: 2019 end-page: 189 ident: CR2 article-title: Prevalence of retinal vein occlusion in Europe: A systematic review and meta-analysis publication-title: Ophthalmologica doi: 10.1159/000494224 – volume: 40 start-page: 1 year: 2011 end-page: 29 ident: CR11 article-title: The split-apply-combine strategy for data analysis publication-title: J. Stat. Softw. doi: 10.18637/jss.v040.i01 – volume: 255 start-page: 77 year: 2017 end-page: 87 ident: CR14 article-title: Dexamethasone intravitreal implant in retinal vein occlusion: Real-life data from a prospective, multicenter clinical trial publication-title: Graefes Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-016-3431-x – volume: 124 start-page: 726 year: 2006 end-page: 732 ident: CR3 article-title: Ten-year incidence of retinal vein occlusion in an older population: The Blue Mountains Eye Study publication-title: Arch. Ophthalmol. doi: 10.1001/archopht.124.5.726 – volume: 2020 start-page: 6830148 year: 2020 ident: CR23 article-title: Morphological and functional outcomes after intravitreal dexamethasone injection for macular edema in patients with central vein occlusion at 48-week follow-up publication-title: J. Ophthalmol. doi: 10.1155/2020/6830148 – volume: 2017 start-page: 5831682 year: 2017 ident: CR13 article-title: Switch of intravitreal therapy for macular edema secondary to retinal vein Occlusion from anti-VEGF to dexamethasone implant and vice versa publication-title: J. Ophthalmol. doi: 10.1155/2017/5831682 – volume: 55 start-page: 152 year: 2016 end-page: 158 ident: CR15 article-title: Retinal vein occlusions: Therapeutic switch in macular oedema treatment with a 12-month follow-up publication-title: Ophthalm. Res. doi: 10.1159/000442258 – volume: 21 start-page: 1 year: 2007 end-page: 20 ident: CR12 article-title: Reshaping data with the reshape package publication-title: J. Stat. Softw. doi: 10.18637/jss.v021.i12 – volume: 38 start-page: 330 year: 2019 end-page: 337 ident: CR21 article-title: Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: A 12-month prospective study publication-title: Cutan. Ocul. Toxicol. doi: 10.1080/15569527.2019.1614020 – volume: 118 start-page: 2453 year: 2011 end-page: 2460 ident: CR19 article-title: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.05.014 – volume: 54 start-page: 540 year: 2019 end-page: 547 ident: CR22 article-title: Ozurdex for refractory macular edema secondary to diabetes, vein occlusion, uveitis and pseudophakia publication-title: Can. J. Ophthalmol. doi: 10.1016/j.jcjo.2018.12.005 – volume: 117 start-page: 1134 year: 2010 end-page: 1146.e3 ident: CR18 article-title: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.03.032 – volume: 256 start-page: 1441 year: 2018 end-page: 1448 ident: CR24 article-title: Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: A 3-year experience publication-title: Graefes. Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-018-4016-7 – volume: 247 start-page: 137 year: 2009 end-page: 142 ident: CR8 article-title: Resolving the clinical acuity categories ‘hand motion’ and ‘counting fingers’ using the Freiburg Visual Acuity Test (FrACT) publication-title: Graefes Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-008-0926-0 – volume: 181 start-page: 98 year: 2019 end-page: 104 ident: CR6 article-title: Impact of angiogenic activation and inhibition on miRNA profiles of human retinal endothelial cells publication-title: Exp. Eye Res. doi: 10.1016/j.exer.2019.01.006 – volume: 111 start-page: 44 year: 2014 end-page: 52 ident: CR20 article-title: Reliability and safety of intravitreal Ozurdex injections. The ZERO study publication-title: Ophthalmologe doi: 10.1007/s00347-012-2737-2 – volume: 117 start-page: 313 year: 2010 end-page: 319.e1 ident: CR1 article-title: The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.07.017 – volume: 238 start-page: 110 year: 2017 end-page: 118 ident: CR17 article-title: Comparison of intravitreal ranibizumab, aflibercept, and dexamethasone implant after bevacizumab failure in macular edema secondary to retinal vascular occlusions publication-title: Ophthalmologica doi: 10.1159/000473864 – year: 2014 ident: CR10 publication-title: R: A Language and Environment for Statistical Computing – volume: 117 start-page: 1113 year: 2010 end-page: 1123.e15 ident: CR4 article-title: Natural history of central retinal vein occlusion: An evidence-based systematic review publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.01.060 – volume: 47 start-page: 1236 year: 2006 end-page: 1240 ident: CR9 article-title: Visual acuities ‘hand motion’ and ‘counting fingers’ can be quantified with the freiburg visual acuity test publication-title: Invest. Ophthalmol. Vis. Sci. doi: 10.1167/iovs.05-0981 – volume: 67 start-page: 1800 year: 2019 end-page: 1809 ident: CR5 article-title: Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials publication-title: Indian J. Ophthalmol. doi: 10.4103/ijo.IJO_382_19 – volume: 256 start-page: 267 year: 2018 end-page: 279 ident: CR16 article-title: Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months publication-title: Graefes Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-017-3852-1 – volume: 9 start-page: 3301 year: 2019 ident: CR7 article-title: Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment publication-title: Sci. Rep. doi: 10.1038/s41598-019-38934-8 – volume: 256 start-page: 1441 year: 2018 ident: 87467_CR24 publication-title: Graefes. Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-018-4016-7 – volume: 40 start-page: 1 year: 2011 ident: 87467_CR11 publication-title: J. Stat. Softw. – volume: 238 start-page: 110 year: 2017 ident: 87467_CR17 publication-title: Ophthalmologica doi: 10.1159/000473864 – volume: 38 start-page: 330 year: 2019 ident: 87467_CR21 publication-title: Cutan. Ocul. Toxicol. doi: 10.1080/15569527.2019.1614020 – volume: 111 start-page: 44 year: 2014 ident: 87467_CR20 publication-title: Ophthalmologe doi: 10.1007/s00347-012-2737-2 – volume: 117 start-page: 1134 year: 2010 ident: 87467_CR18 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.03.032 – volume: 117 start-page: 313 year: 2010 ident: 87467_CR1 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2009.07.017 – volume: 181 start-page: 98 year: 2019 ident: 87467_CR6 publication-title: Exp. Eye Res. doi: 10.1016/j.exer.2019.01.006 – volume: 256 start-page: 267 year: 2018 ident: 87467_CR16 publication-title: Graefes Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-017-3852-1 – volume: 124 start-page: 726 year: 2006 ident: 87467_CR3 publication-title: Arch. Ophthalmol. doi: 10.1001/archopht.124.5.726 – volume: 255 start-page: 77 year: 2017 ident: 87467_CR14 publication-title: Graefes Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-016-3431-x – volume-title: R: A Language and Environment for Statistical Computing year: 2014 ident: 87467_CR10 – volume: 2017 start-page: 5831682 year: 2017 ident: 87467_CR13 publication-title: J. Ophthalmol. doi: 10.1155/2017/5831682 – volume: 117 start-page: 1113 year: 2010 ident: 87467_CR4 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2010.01.060 – volume: 67 start-page: 1800 year: 2019 ident: 87467_CR5 publication-title: Indian J. Ophthalmol. doi: 10.4103/ijo.IJO_1905_18 – volume: 55 start-page: 152 year: 2016 ident: 87467_CR15 publication-title: Ophthalm. Res. doi: 10.1159/000442258 – volume: 247 start-page: 137 year: 2009 ident: 87467_CR8 publication-title: Graefes Arch. Clin. Exp. Ophthalmol. doi: 10.1007/s00417-008-0926-0 – volume: 47 start-page: 1236 year: 2006 ident: 87467_CR9 publication-title: Invest. Ophthalmol. Vis. Sci. doi: 10.1167/iovs.05-0981 – volume: 118 start-page: 2453 year: 2011 ident: 87467_CR19 publication-title: Ophthalmology doi: 10.1016/j.ophtha.2011.05.014 – volume: 9 start-page: 3301 year: 2019 ident: 87467_CR7 publication-title: Sci. Rep. doi: 10.1038/s41598-019-38934-8 – volume: 54 start-page: 540 year: 2019 ident: 87467_CR22 publication-title: Can. J. Ophthalmol. doi: 10.1016/j.jcjo.2018.12.005 – volume: 21 start-page: 1 year: 2007 ident: 87467_CR12 publication-title: J. Stat. Softw. doi: 10.18637/jss.v021.i12 – volume: 241 start-page: 183 year: 2019 ident: 87467_CR2 publication-title: Ophthalmologica doi: 10.1159/000494224 – volume: 2020 start-page: 6830148 year: 2020 ident: 87467_CR23 publication-title: J. Ophthalmol. |
SSID | ssj0000529419 |
Score | 2.3453329 |
Snippet | Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of... Abstract Macular edema (ME) is the most frequent vision threatening consequence after retinal vein occlusion (RVO). In this study, we evaluate the effect of... |
SourceID | doaj pubmedcentral proquest pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 8303 |
SubjectTerms | 692/308 692/699/3161/3175 Acuity Cataracts Corticoids Corticosteroids Dexamethasone Edema Electronic medical records Eye Humanities and Social Sciences multidisciplinary Occlusion Patients Retina Science Science (multidisciplinary) Steroids Surgery Transplants & implants Vascular endothelial growth factor |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhUOilNE0fbtKiQm-tiWTJkn1sS0MINIfSQG5CT2pwdpdknSb_vjOyd5NNX5cebclomJc-eUYzhLwNNkrVRFU2FU-l1DJgkNCWtrGxdjwmn7Pdv5yoo1N5fFaf3Wn1hTlhY3ngkXEHVnGwA5ZCA9gZTgfOxsoJEZlOnLGYvS_seXcOU2NV76qVvJ1uyTDRHFzCToW3ySoODgC9g9rYiXLB_t-hzF-TJe9FTPNGdPiYPJoQJP0wUr5DtuLsCXkw9pS82SXxK0C_su9SpBg3H84pOl-aQN7zH-WwoJgTCo8XtMOVrjpMNe9piNcWu0lbwN-RdueLHlgOUyjecsT1riI8zL3vB_y_9pScHn7-9umonHoplB4w2bLUnvugHWt1AqDKgxXK1SqAvTruBRgl91wHFpXWtQbIwLwDHqsqORGCY0E8I9szIOAFoVXlAfQJIQPAr9gEJ4NMbfDWShSQKAhf8dX4qdA49rvoTQ54i8aMsjAgC5NlYVRB3q2_WYxlNv46-yOKaz0TS2TnF6A4ZlIc8y_FKcj-SthmsttLA2hPsBZgIQy_WQ-DxWEYxc7ifMhzpALfp2VBno-6saYEDvw1nGiBB3pDazZI3RyZdd9zVe-Gwaq6Lcj7lX7dkvVnVrz8H6zYIw8rNAwsYVnvk-3lxRBfAdZautfZrH4CzeYkDQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCIkL4t1AQUbiBlHt2LGTEwJEVSHBAVFpb5ZfgUjpZtndFPj3zDjZVMujx2y88sTz-uwZzxDyItgoVRVVXhW8yaWWAYOENreVjaXjsfEp2_3jJ3V6Jj8sysV04LaZ0ip3NjEZ6tB7PCM_Bj8sWA0Ou3i9-p5j1yiMrk4tNK6TG1i6DFO69ELPZywYxZK8nu7KMFEdb8Bf4Z2ygoMZQBuh9vxRKtv_L6z5d8rkH3HT5I5O7pDbE46kb0bG3yXX4vIeuTl2lvx1n8TPAADzrm0ixej5cE7RBNMGuN7_yIcVxcxQeFzTFme6aDHhvKMh_rTYU9oCCo-0PV91sPAwhOJdR5zvIsJD73034CnbA3J28v7Lu9N86qiQe0Bm21x77oN2rNYNwFUerFCuVAG01nEvQDW55zqwqLQuNQAH5p2ITBWNEyE4FsRDcrAEAg4JLQoP0E8IGQCExSo4GWRTB2-thB1NLTLCd-tq_FRuHLtedCaFvUVlRl4Y4IVJvDAqIy_n_6zGYhtXjn6L7JpHYqHs9EO__momvTNWcTCjrAkVbL2ALmdj4QR8lG44Y7HIyNGO2WbS3o25lLWMPJ9fg95hMMUuYz-kMVKBBdQyI49G2ZgpgW1_CftaWAO9JzV7pO6_WbbfUm3visGsus7Iq518XZL1_6V4fPVXPCG3ChR5LFFZHpGD7XqITwFLbd2zpDC_AU2vHCo priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3daxQxEA-1Ivgi9Xu1SgTfdDHZZJPdx3pYiqAPYqFvIV-rC9u743rb1v_emeyHnFbBx2wmZDYzk_ySmUwIeR1slKqKKq8K3uRSy4BOQpvbysbS8dj4FO3-6bM6OZUfz8qzPVJMd2FS0H5KaZmm6Sk67N0FLDR4GazgYL9o3OoWuY2p21GrF2oxn6ug50ryerwfw0R1Q9OdNSil6r8JX_4ZJvmbrzQtQccH5N6IHenRwO19sheXD8id4TXJHw9J_AKgL-_aJlL0mPfnFKdd2oCkV1d5v6YYDQrFDW2xp8sWg8w7GuK1xXekLSDvSNvzdQeDDSQU7zdif5cRCivvux5P1h6R0-MPXxcn-fiKQu4BjW1z7bkP2rFaNwBRebBCuVIFsFTHvQBz5J7rwKLSutQAFph3IjJVNE6E4FgQj8n-Ehh4SmhReIB7QsgAwCtWwckgmzp4ayXsYmqRET6Nq_FjinF86aIzydUtKjPIwoAsTJKFURl5M7dZDwk2_kn9HsU1U2Jy7PRhtflmRmUxVnGYOlkTKthuAV_OxsIJ-CndcMZikZHDSdhmtNgLAzhPsBoAIVS_mqvB1tCBYpdx1ScaqWDW0zIjTwbdmDmBrX4Je1kYA72jNTus7tYs2-8pn3fFoFddZ-TtpF-_2Pr7UDz7P_Ln5G6BJoBpKstDsr_d9PEF4Kmte5kM6Cfwjxos priority: 102 providerName: Springer Nature |
Title | Real-life medium term follow-up data for intravitreal dexamethasone implant in retinal vein occlusion |
URI | https://link.springer.com/article/10.1038/s41598-021-87467-6 https://www.ncbi.nlm.nih.gov/pubmed/33859243 https://www.proquest.com/docview/2513092502 https://www.proquest.com/docview/2514604074 https://pubmed.ncbi.nlm.nih.gov/PMC8050279 https://doaj.org/article/a618870fd8174289bae2b33e07f100e2 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELf2ISReEN-EjSpIvEEgjh07eUCoqzZNlTahQaW-Rf4KRMra0jX7-O-5c5KiQkHiKUrsxte7-9k_x_YdIW-sclxkTkRZQsuIS25xkVBFKlMu1dSVxu92PzsXpxM-nqbTHdKnO-oUeLV1aof5pCbL-v3tj7tPAPiP7ZHx7MMVDEJ4UCyhgG0Evtgl-zAySQTqWUf321jfSc59rg8Mwh4BmUi6czTbX7MxVvmQ_tt46J_bKX9bU_VD1clD8qDjmOGwdYpHZMfNHpN7bdbJuyfEXQA5jOqqdCGurDeXIXbPYQkeMb-JmkWIu0bhdhlW2NJ1hZvR69C6W4X5phUwdBdWl4sajAJVQjwHie1dO7iZG1M3-AXuKZmcHH8dnUZdtoXIAGtbRdJQY6WOc1kClaVWMaFTYQHRmhoGsKWGShs7IWUqgVTERjMXi6TUzFodW_aM7M1AgBckTBIDtJAxboGgucxqbnmZW6MUh9lOzgJCe70WpgtFjhkx6sIvibOsaG1RgC0Kb4tCBOTt-jeLNhDHP2sfobnWNTGItn8wX34rOkwWSlDoYuPSZjAtA7m0colm8KdkSePYJQE57I1d9I5ZAB9kcQ7EEYpfr4sBk7jQomZu3vg6XEDvKHlAnre-sZaEsSyFOS_oQG54zYaomyWz6ruP-53F0KrMA_Ku969fYv1dFS__S3EH5H6CCMBolukh2VstG_cKaNdKD8iunMoB2R8Ox1_GcD06Pv98AU9HYjTwnzIGHm0_Ae_tKws |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwELbKVgheEDeBAkGCJ4gaH7GTB4QotNrSdoWqVuqb6yt0pe3udo-W_il-IzM5tlqOvvUxiRNPPJ_n8NgzhLz1JgiZB5nkjJaJUMJjkNAkJjchszSUrtrtvteT3UPx7Sg7WiG_2rMwuK2ylYmVoPYjh2vk66CHeVqAwmafxmcJVo3C6GpbQqOGxU64vACXbfpx-yvw9x1jW5sHX7pJU1UgcWCdzBLlqPPKpoUqwWSj3nBpM-kBuZY6DvCkjiqfBqlUpkB5ps7ykEpWWu69TT2H794iq4KDK9Mhqxubve_7i1UdjJsJWjSnc1Ker09BQ-IpNkZB8KBUkksasCoU8C_r9u9Nmn9EaisFuHWf3Gss1_hzDbUHZCUMH5LbdS3Ly0ck7IPJmQz6ZYgxXj8_jVHoxyXgbHSRzMcx7kWFy0ncx57O-7jFfRD78NNgFWsDdn-I-6fjAbAamsR4uhL7Ow9wMXJuMMd1vcfk8EZG-wnpDIGAZyRmzIGxybnwYPaF3FvhRVl4Z4wAH6rgEaHtuGrXJDjHOhsDXQXaea5rXmjgha54oWVE3i_eGdfpPa5tvYHsWrTE1NzVjdHkh25mujaSguBOS5-Dswd0WROY5fBTqqRpGlhE1lpm60ZeTPUVuiPyZvEYZjqGb8wwjOZVGyFB5ioRkac1NhaUcJ5n4EnDGKgl1CyRuvxk2D-psonnKfSqioh8aPF1Rdb_h-L59X_xmtzpHuzt6t3t3s4Lcpch_DFBZrZGOrPJPLwES25mXzXTJybHNz1jfwO8iloN |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtQw0CpFIF4QN4ECRoIniNZX7OQBIaCsWgoVQlTaN9exHVhpu7vs0dJf4-uYybHVcvStj0mceOK5PeMZQp4FF5XOo05zwatUGRUwSOhSl7uYlTxWvs52_7Svdw7Uh0E22CC_urMwmFbZycRaUIeJxz3yHuhhyQpQ2KJXtWkRn7f7r6c_UuwghZHWrp1GQyJ78fQE3Lf5q91twPVzIfrvv77bSdsOA6kHS2WRGs99MCUrTAXmGw9O6jLTAai45F4CqXLPTWBRG5MZUKTMlzIyLapShlCyIOG7l8hlIwE44CUzMKv9HYygKV6053SYzHtz0JV4nk1wEEEon_SaLqxbBvzLzv07XfOPmG2tCvs3yPXWhqVvGqK7STbi-Ba50nS1PL1N4hcwPtPRsIoUI_fLI4rin1ZAcZOTdDmlmJUKlzM6xJmOh5jsPqIh_nTYz9qBBxDp8Gg6AqTDEIrnLHG-4wgXE-9HS9zhu0MOLmSt75LNMQBwn1AhPJidUqoABmDMQ6mCqorgnVPgTRUyIbxbV-vbUufYcWNk65C7zG2DCwu4sDUurE7Ii9U706bQx7mj3yK6ViOxSHd9YzL7Zluet05zEOGsCjm4fQBX6aIoJfyUqThjUSRkq0O2bSXH3J7ReUKerh4Dz2Mgx43jZFmPURqkr1EJudfQxgoSKfMMfGpYA7NGNWugrj8ZD7_XdcVzBrOaIiEvO_o6A-v_S_Hg_L94Qq4Cn9qPu_t7D8k1gdSPlTKzLbK5mC3jIzDpFuXjmncoObxoZv0NDxRc3Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-life+medium+term+follow-up+data+for+intravitreal+dexamethasone+implant+in+retinal+vein+occlusion&rft.jtitle=Scientific+reports&rft.au=Wecker%2C+Thomas&rft.au=Grundel%2C+Bastian&rft.au=Grundel%2C+Milena&rft.au=Br%C3%BCnder%2C+Marie-Christine&rft.date=2021-04-15&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-021-87467-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_021_87467_6 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |